StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK) PT Lowered to $69 at Leerink Partners
October 30, 2017 7:49 AM
Leerink Partners lowered its price target on Merck (NYSE ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Next Articles
Jefferies Upgrades Merck (MRK) to Hold
October 31, 2017 3:51 AM
Merck (MRK) PT Lowered to $67 at UBS on 'Keynote-189 Delay As Feared'
October 30, 2017 10:45 AM
Merck (MRK) PT Lowered to $64 at Bernstein
October 30, 2017 8:09 AM
SunTrust Robinson Humphrey Downgrades Merck (MRK) to Hold
October 30, 2017 5:26 AM
Morgan Stanley Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:11 AM
Barclays Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:05 AM
Merck (MRK) Withdraws European Application for KEYTRUDA in Combination with Pemetrexed and Carboplatin for First-Line Treatment of NSCLC
October 27, 2017 4:18 PM
Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
October 27, 2017 4:17 PM
Wall St. powered higher by tech, Amazon results
October 27, 2017 7:38 AM
Form 8-K Merck & Co., Inc. For: Oct 27
October 27, 2017 6:59 AM
Merck (MRK) Tops Q3 EPS by 8c, Lifts FY EPS Gudiance
October 27, 2017 6:46 AM
Merck Announces Third-Quarter 2017 Financial Results
October 27, 2017 6:45 AM
